AbbVie Inc.

05/12/2026 | Press release | Distributed by Public on 05/12/2026 15:02

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting.

(1) The stockholders elected AbbVie's Class II directors with terms expiring in 2029, as follows:
Name For Against Abstain Broker Non-Votes
Jennifer L. Davis 1,216,558,754 89,839,329 2,680,369 239,399,581
Melody B. Meyer 1,284,771,578 22,470,074 1,836,800 239,399,581
Robert A. Michael 1,221,224,370 85,865,852 1,988,230 239,399,581
Frederick H. Waddell 1,225,237,825 81,747,033 2,093,594 239,399,581
(2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026, as follows:
For Against Abstain
1,522,575,012 23,766,564 2,136,457
(3) The stockholders approved, on an advisory basis, the compensation of AbbVie's named executive officers, as follows:
For Against Abstain Broker Non-Votes
1,228,615,745 69,336,359 11,126,348 239,399,581
(4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:
For Against Abstain Broker Non-Votes
1,290,990,023 14,896,119 3,192,310 239,399,581
(5) The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:
For Against Abstain Broker Non-Votes
515,626,009 787,253,970 6,198,473 239,399,581
AbbVie Inc. published this content on May 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 12, 2026 at 21:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]